Market brief

Swiss vs German Biotech Manufacturing 2026: A Practical Comparison

Switzerland and Germany together anchor European biotech manufacturing, but they play different roles. Switzerland hosts large-integrated biologics specialists (Lonza), peptide leaders (Bachem), plasma and biosimilars specialists (Octapharma, Sandoz), and precision-device partners (Siegfried, Ypsomed). Germany hosts the deepest mid-to-large CDMO layer in Europe (Rentschler, Vetter, IDT Biologika, Wacker Biotech, ProBioGen) alongside pharma manufacturers (Merck KGaA, Gerresheimer) and vaccine capacity. In 2026, the practical choice between the two countries depends on what is being manufactured: for clinical-to-commercial biologics at scale, Switzerland leads on brand and integration, Germany on breadth of mid-cap CDMO capacity and geographic redundancy.

Summary

Key findings

Lonza (Visp) remains the European reference for large-scale biologics and ADC manufacturing - clinical-to-commercial integration in one site is its structural advantage.
Rentschler Biopharma (Laupheim) anchors the German biologics CDMO layer with a clinical-to-commercial posture and a published regulatory track record - the closest direct competitor to Lonza for mid-cap biologics programmes.
Germany offers substantially more CDMO operators in the mid-cap and specialised-service tiers - Vetter (sterile fill-finish), IDT Biologika (vaccines and viral vectors), Wacker Biotech (microbial), ProBioGen (cell-line services) - giving sponsors more supply-chain redundancy.
Switzerland’s specialisation is in high-margin anchors: Bachem for peptides, Octapharma for plasma derivatives, Sandoz for biosimilars, Siegfried for API/CDMO, Ypsomed for drug-delivery devices. Germany’s strength is in the sheer count and geographic distribution of biologics-capable sites.
First-pass shortlist

Choose the manufacturing path before choosing the country

Switzerland and Germany are complementary manufacturing markets, not interchangeable labels. These routes use publicly stated scope to form a first-call group; confirm site-level capability, quality requirements, capacity, and commercial terms directly with every supplier.

Large integrated biologics

Clinical-to-commercial biologics or ADC manufacturing

Visp, Switzerland

Publicly stated scope
Start with Lonza when the programme calls for a large integrated biologics, ADC, or advanced-therapy manufacturing discussion at the Visp scale described publicly.
Confirm first
Modality and expression system, clinical or commercial phase, drug-substance and drug-product handoff, analytical and release-testing model, technology transfer, and the named site or network route.
Do not assume
That a large integrated network confirms fit, an available slot, or that every service can be delivered at one site for the specific programme.
Peptide or oligonucleotide API

Synthetic peptide, oligonucleotide, or conjugate supply

Bubendorf, Switzerland

Publicly stated scope
Start with Bachem for its publicly stated peptide and oligonucleotide manufacturing scope when the critical purchase is synthetic API rather than biologics drug substance.
Confirm first
Sequence and chemistry, GMP phase, scale, impurity and analytical package, conjugation requirements, regulatory market, and the downstream formulation or fill-finish handoff.
Do not assume
That peptide or oligonucleotide capability means a specific chemistry, conjugation route, scale, or finished-drug-product route is available.
Sterile drug product

Aseptic injectables, syringes, cartridges, or vials

Ravensburg, Germany

Publicly stated scope
Start with Vetter Pharma for a publicly described sterile fill-finish discussion around prefilled syringes, cartridges, and vials, then map drug substance and device requirements separately.
Confirm first
Presentation, fill volume, formulation, primary container and closure, device assembly, visual inspection, batch scale, cold-chain needs, and the qualified drug-substance transfer path.
Do not assume
That fill-finish scope automatically covers the required device combination, inspection regime, packaging, or product-specific commercial campaign.
Specialised German modality

Biologics development, vaccines, viral vectors, microbial production, or cell-line work

Laupheim, Dessau-Rosslau, Jena, and Berlin

Publicly stated scope
Route by modality: Rentschler for biologics CDMO, IDT Biologika for vaccine and viral-vector scope, Wacker Biotech for microbial production, or ProBioGen for cell-line development and CHO services.
Confirm first
The exact modality, host or vector system, development stage, containment requirements, analytics, comparability package, expected scale, and which German site would own the work.
Do not assume
That Germany’s wider supplier base makes these specialists interchangeable or confirms that a named site accepts the programme.
Dual-country manufacturing strategy

A deliberate split between drug substance, drug product, and a second source

Switzerland and Germany

Publicly stated scope
Use a Swiss drug-substance or API partner alongside a German drug-product or specialist partner only after defining the handoffs, legal entities, quality agreement, logistics, and release-testing responsibilities.
Confirm first
Where ownership changes, which site releases each material, transport and customs requirements, comparability and stability data, audit rights, change control, and contingency arrangements.
Do not assume
That nearby countries, GDP logistics, or familiar brand names remove the need for a documented cross-border manufacturing and quality plan.
Numbers

Quick numbers

Swiss biologics anchorLonza (Visp)Large-scale biologics + ADC
German biologics anchorRentschler (Laupheim)Clinical-to-commercial CDMO
Swiss peptide leaderBachem (Bubendorf)Peptides, oligo-peptide conjugates
German sterile fill-finishVetter (Ravensburg)Top-tier sterile biologics
Analysis

What Switzerland is best at in 2026

Switzerland’s biotech manufacturing brand is built around Lonza. The Visp site anchors large-scale biologics and antibody-drug conjugate capacity in a way that is still hard to match elsewhere in Europe. Around Lonza, the rest of the Swiss picture specialises: Bachem (Bubendorf) on peptides and oligonucleotide-peptide conjugates, Octapharma (Lachen) on plasma derivatives, Sandoz (Basel) on biosimilars and generics at scale, Siegfried (Zofingen) on API and small-molecule CDMO, and Ypsomed (Burgdorf) on drug-delivery devices. Pharma anchors (Roche, Novartis) sit behind these as demand drivers. The net effect is a small but deep manufacturing base where each company is a category leader.

Analysis

What Germany is best at in 2026

Germany’s manufacturing case is different: more operators, more regional distribution, more specialisation breadth. Rentschler Biopharma (Laupheim) is the closest German parallel to Lonza for mid-cap biologics, with a published regulatory track record. Vetter Pharma (Ravensburg) holds a top-tier position in sterile fill-finish for biologics. IDT Biologika (Dessau-Rosslau) adds viral-vector and vaccine capacity - including COVID-era large-scale vaccine manufacturing. Wacker Biotech (Halle/Jena) specialises in microbial fermentation. ProBioGen (Berlin) adds cell-line development and high-yield CHO services. Merck KGaA (Darmstadt) and Gerresheimer (Düsseldorf) sit behind this layer as pharma and pharma-packaging anchors.

Analysis

How to choose between Switzerland and Germany for a given programme

A practical decision rule: programmes that need large-integrated biologics capacity in one site, plus the Lonza brand signal for partners and investors, land in Switzerland. Programmes that need mid-cap clinical-to-commercial biologics, sterile fill-finish alongside drug substance, or specialised services (vaccines, viral vectors, microbial fermentation) find more optionality in Germany. Programmes that need peptides or oligo-peptide conjugates go to Bachem in Switzerland almost regardless of other criteria. Programmes that need geographic redundancy across multiple sites should probably use Germany as the primary country simply because there are more operators to choose from.

Analysis

Pricing and capacity signal - what to check in 2026

Capacity and pricing in 2026 are not in the published record in any way that is meaningful for a sponsor. Both Switzerland and Germany are under meaningful demand pressure in biologics, ADC, and sterile fill-finish. What sponsors can verify: published inspection history (EMA, FDA), known regulatory findings, public statements on capacity expansion (Lonza Visp expansions, Rentschler and Vetter expansions have all been disclosed publicly), and the depth of the mid-cap CDMO alternative layer - which is where a second-source strategy usually lands.

Analysis

Logistics and cross-border reality

Switzerland is not in the EU but is deeply integrated operationally - it participates in the single market for most purposes and uses GDP-aligned pharmaceutical logistics through the same operators (DHL Life Sciences & Healthcare, World Courier, Kuehne+Nagel Healthcare) that cover Germany. Cross-border movement between Swiss manufacturing and German partners, or from Swiss sites to Polish and Baltic nodes, runs on commercial GDP rails. For a sponsor planning a manufacturing footprint, Switzerland is not a friction layer - but FDA/EMA cross-regulatory planning, tariff codes, and release testing should be mapped early.

What to watch

What to watch next

Lonza Visp capacity expansion announcements
Rentschler and Vetter capacity additions - mid-cap CDMO supply dynamics
Swiss-German cross-regulatory coordination (Swissmedic ↔ EMA ↔ FDA) for 2026–2027 launches
ADC manufacturing pricing and capacity signals on both sides
Biosimilar pipeline decisions at Sandoz (Basel) and impact on biosimilar supply
FAQ

Frequently asked questions

Who is the biggest biologics manufacturer in Europe - Lonza or Rentschler?

Lonza is materially larger by revenue and site scale and holds a broader service portfolio (biologics, ADC, cell and gene therapy, capsules, small molecule). Rentschler is focused on biologics CDMO and is a top reference for mid-cap programmes moving from clinical to commercial. For a biologics sponsor, both are first-tier European options; the selection depends on programme size, integration requirements, and brand signal.

Is Switzerland still worth it for biotech manufacturing given it’s not in the EU?

Yes. Switzerland is operationally integrated into European pharmaceutical logistics, uses the same GDP framework, and ships under EU-aligned commercial terms. The regulatory interface with EMA is through established pathways, and Swiss manufacturing remains a premium signal for brand, quality, and scale. The one thing to plan for is FDA/EMA-plus-Swissmedic coordination where relevant.

Where does Germany outperform Switzerland for biotech manufacturing?

Germany has more mid-cap CDMO operators (Rentschler, Vetter, IDT Biologika, Wacker Biotech, ProBioGen), broader geographic distribution, and stronger specialisation options for vaccines, viral vectors, and microbial fermentation. For sponsors pursuing a second-source strategy, Germany typically offers more optionality simply because there are more operators.

Where should I go for peptide manufacturing in Europe?

Bachem (Bubendorf, Switzerland) is the first-tier European peptide manufacturer for most peptide and peptide-conjugate programmes. Germany has peptide capabilities too, but Bachem is the reference.

Can I run fill-finish in Germany and drug substance in Switzerland?

Yes. This is a common split. Vetter (Germany) for sterile fill-finish, Lonza (Switzerland) for drug substance is the canonical version. Commercial GDP logistics and EU-aligned cross-border operations handle the transfer; regulatory and release-testing planning needs to be deliberate.

Methodology note

Sources and interpretation

Sources: verified Memel Biotech directory entries for each manufacturer, official company capability pages, public regulatory and facility disclosures, and editorial comparison of published manufacturing scope.

Disclaimer

Use limits

This brief is an editorial map of visible Swiss and German biotech manufacturing in 2026. Capacity, pricing, and available slots are not public in a reliable way and change constantly - sponsors should verify directly with each manufacturer.

Primary sources

Source list

Lonza biologics capability overviewRentschler Biopharma CDMO servicesVetter Pharma sterile manufacturingBachem peptide and oligonucleotide manufacturingIDT Biologika vaccine and viral vector manufacturing
Related pages

Related directory records

Verification methodologyLithuania biotech page (LT)
Briefs

Continue through related topics.

A useful brief should help people move into related records, cities, categories, and methodology pages without falling back into generic template language.

All briefsDirectory home